Search

Rasem Mourad

Examiner (ID: 7274, Phone: (571)270-7770 , Office: P/2836 )

Most Active Art Unit
2836
Art Unit(s)
2836
Total Applications
617
Issued Applications
444
Pending Applications
46
Abandoned Applications
142

Applications

Application numberTitle of the applicationFiling DateStatus
Array ( [id] => 14896945 [patent_doc_number] => 20190292238 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-09-26 [patent_title] => CD20 THERAPIES, CD22 THERAPIES, AND COMBINATION THERAPIES WITH A CD19 CHIMERIC ANTIGEN RECEPTOR (CAR)- EXPRESSING CELL [patent_app_type] => utility [patent_app_number] => 16/256731 [patent_app_country] => US [patent_app_date] => 2019-01-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 168164 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16256731 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/256731
CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell Jan 23, 2019 Issued
Array ( [id] => 14583953 [patent_doc_number] => 20190219585 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-07-18 [patent_title] => IMMUNOHISTOCHEMICAL PROXIMITY ASSAY FOR PD-1 POSITIVE CELLS AND PD-LIGAND POSITIVE CELLS IN TUMOR TISSUE [patent_app_type] => utility [patent_app_number] => 16/250721 [patent_app_country] => US [patent_app_date] => 2019-01-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21349 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16250721 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/250721
IMMUNOHISTOCHEMICAL PROXIMITY ASSAY FOR PD-1 POSITIVE CELLS AND PD-LIGAND POSITIVE CELLS IN TUMOR TISSUE Jan 16, 2019 Abandoned
Array ( [id] => 19263707 [patent_doc_number] => 20240207404 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-27 [patent_title] => BISPECIFIC IN TANDEM RECEPTOR CAR AND METHOD FOR MODULATING THE TUMORAL MICROENVIRONMENT [patent_app_type] => utility [patent_app_number] => 17/420739 [patent_app_country] => US [patent_app_date] => 2019-01-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9547 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17420739 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/420739
Bispecific in tandem receptor car and method for modulating the tumoral microenvironment Jan 6, 2019 Issued
Array ( [id] => 17859823 [patent_doc_number] => 11440969 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-09-13 [patent_title] => Use of human epididymis protein 4 (HE4) for assessing responsiveness of MUC 16-positive cancer treatment [patent_app_type] => utility [patent_app_number] => 16/239663 [patent_app_country] => US [patent_app_date] => 2019-01-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 27 [patent_no_of_words] => 61413 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 148 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16239663 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/239663
Use of human epididymis protein 4 (HE4) for assessing responsiveness of MUC 16-positive cancer treatment Jan 3, 2019 Issued
Array ( [id] => 15666429 [patent_doc_number] => 10597432 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-03-24 [patent_title] => Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers [patent_app_type] => utility [patent_app_number] => 16/237284 [patent_app_country] => US [patent_app_date] => 2018-12-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 25 [patent_no_of_words] => 46004 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 96 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16237284 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/237284
Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers Dec 30, 2018 Issued
Array ( [id] => 15163293 [patent_doc_number] => 10487126 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-11-26 [patent_title] => Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers [patent_app_type] => utility [patent_app_number] => 16/237279 [patent_app_country] => US [patent_app_date] => 2018-12-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 25 [patent_no_of_words] => 46032 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 98 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16237279 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/237279
Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers Dec 30, 2018 Issued
Array ( [id] => 20622639 [patent_doc_number] => 12590137 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-03-31 [patent_title] => Meditope-enabled T cells [patent_app_type] => utility [patent_app_number] => 16/958614 [patent_app_country] => US [patent_app_date] => 2018-12-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 50 [patent_figures_cnt] => 64 [patent_no_of_words] => 31536 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16958614 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/958614
Meditope-enabled T cells Dec 30, 2018 Issued
Array ( [id] => 14185285 [patent_doc_number] => 20190112347 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-04-18 [patent_title] => Novel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers [patent_app_type] => utility [patent_app_number] => 16/233284 [patent_app_country] => US [patent_app_date] => 2018-12-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 45939 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 96 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16233284 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/233284
Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers Dec 26, 2018 Issued
Array ( [id] => 16375078 [patent_doc_number] => 20200323920 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-15 [patent_title] => IMMUNOCOMPETENT CELL THAT EXPRESSES A CELL SURFACE MOLECULE SPECIFICALLY RECOGNIZING HUMAN MESOTHELIN, IL-7 AND CCL19 [patent_app_type] => utility [patent_app_number] => 16/956855 [patent_app_country] => US [patent_app_date] => 2018-12-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21244 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16956855 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/956855
IMMUNOCOMPETENT CELL THAT EXPRESSES A CELL SURFACE MOLECULE SPECIFICALLY RECOGNIZING HUMAN MESOTHELIN, IL-7 AND CCL19 Dec 18, 2018 Abandoned
Array ( [id] => 14652713 [patent_doc_number] => 20190233485 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-01 [patent_title] => T CELL RECEPTORS DIRECTED AGAINST BOB1 AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/213368 [patent_app_country] => US [patent_app_date] => 2018-12-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 54590 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16213368 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/213368
T CELL RECEPTORS DIRECTED AGAINST BOB1 AND USES THEREOF Dec 6, 2018 Abandoned
Array ( [id] => 14649461 [patent_doc_number] => 20190231859 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-01 [patent_title] => YEAST-MUC1 IMMUNOTHERAPEUTIC COMPOSITIONS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/211492 [patent_app_country] => US [patent_app_date] => 2018-12-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35385 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16211492 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/211492
Yeast-MUC1 immunotherapeutic compositions and uses thereof Dec 5, 2018 Issued
Array ( [id] => 14375237 [patent_doc_number] => 20190161531 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-30 [patent_title] => Cell [patent_app_type] => utility [patent_app_number] => 16/211538 [patent_app_country] => US [patent_app_date] => 2018-12-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14611 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -1 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16211538 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/211538
Chimeric antigen receptor (CAR) comprising a CD19-binding domain Dec 5, 2018 Issued
Array ( [id] => 17241171 [patent_doc_number] => 20210360914 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-25 [patent_title] => PRODUCTION OF CELL-BASED VACCINES [patent_app_type] => utility [patent_app_number] => 16/763878 [patent_app_country] => US [patent_app_date] => 2018-12-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11852 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16763878 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/763878
PRODUCTION OF CELL-BASED VACCINES Dec 2, 2018 Abandoned
Array ( [id] => 17236680 [patent_doc_number] => 11180552 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-11-23 [patent_title] => CD47 antibodies and uses thereof for treating cancer [patent_app_type] => utility [patent_app_number] => 16/203809 [patent_app_country] => US [patent_app_date] => 2018-11-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 56 [patent_figures_cnt] => 98 [patent_no_of_words] => 44858 [patent_no_of_claims] => 33 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 167 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16203809 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/203809
CD47 antibodies and uses thereof for treating cancer Nov 28, 2018 Issued
Array ( [id] => 14439721 [patent_doc_number] => 20190177733 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-06-13 [patent_title] => CANCER VACCINE FOR DOGS [patent_app_type] => utility [patent_app_number] => 16/197563 [patent_app_country] => US [patent_app_date] => 2018-11-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10956 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16197563 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/197563
CANCER VACCINE FOR DOGS Nov 20, 2018 Abandoned
Array ( [id] => 14043451 [patent_doc_number] => 20190077832 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-03-14 [patent_title] => NOVEL CELL EPITOPES AND COMBINATION OF CELL EPITOPES FOR USE IN THE IMMUNOTHERAPY OF MYELOMA AND OTHER CANCERS [patent_app_type] => utility [patent_app_number] => 16/196812 [patent_app_country] => US [patent_app_date] => 2018-11-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34866 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 160 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16196812 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/196812
Cell epitopes and combination of cell epitopes for use in the immunotherapy of myeloma and other cancers Nov 19, 2018 Issued
Array ( [id] => 17082079 [patent_doc_number] => 20210277085 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-09 [patent_title] => TARGETED IMMUNOTOLERANCE [patent_app_type] => utility [patent_app_number] => 17/053979 [patent_app_country] => US [patent_app_date] => 2018-11-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 59025 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17053979 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/053979
TARGETED IMMUNOTOLERANCE Nov 19, 2018 Abandoned
Array ( [id] => 17020945 [patent_doc_number] => 20210244816 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-12 [patent_title] => CD47 BLOCKADE WITH RADIATION THERAPY [patent_app_type] => utility [patent_app_number] => 16/759981 [patent_app_country] => US [patent_app_date] => 2018-11-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8765 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16759981 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/759981
CD47 blockade with radiation therapy Nov 4, 2018 Issued
Array ( [id] => 14277305 [patent_doc_number] => 20190135937 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-09 [patent_title] => CD-38 Directed Chimeric Antigen Receptor Constructs [patent_app_type] => utility [patent_app_number] => 16/179850 [patent_app_country] => US [patent_app_date] => 2018-11-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25405 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 74 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16179850 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/179850
CD-38 directed chimeric antigen receptor constructs Nov 1, 2018 Issued
Array ( [id] => 17162987 [patent_doc_number] => 11149074 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-10-19 [patent_title] => Azide group-containing Fc protein [patent_app_type] => utility [patent_app_number] => 16/177839 [patent_app_country] => US [patent_app_date] => 2018-11-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 19960 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 49 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16177839 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/177839
Azide group-containing Fc protein Oct 31, 2018 Issued
Menu